Global Health Clinics Valuation

Is MJRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MJRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MJRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MJRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MJRX?

Key metric: As MJRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MJRX. This is calculated by dividing MJRX's market cap by their current revenue.
What is MJRX's PS Ratio?
PS Ratio	1.1x
Sales	CA$86.36k
Market Cap	CA$93.92k

MJRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.4x
Enterprise Value/EBITDA	-1.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MJRX's PS Ratio compare to its peers?

The above table shows the PS ratio for MJRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.6x
OMND Optimind Pharma	4.9x	n/a	CA$548.9k
DELC Delic Holdings	0.08x	n/a	CA$691.5k
NEWU Newtopia	0.1x	n/a	CA$866.3k
VTAL Justera Health	1.4x	n/a	CA$2.7m
MJRX Global Health Clinics	1.1x	n/a	CA$93.9k

Price-To-Sales vs Peers: MJRX is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does MJRX's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
DOC CloudMD Software & Services	0.1x	n/a	US$7.82m
NPTH NeuPath Health	0.1x	n/a	US$6.42m
PHA Premier Health of America	0.05x	4.3%	US$5.72m
BLMH Bloom Health Partners	0.1x	n/a	US$2.85m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MJRX is good value based on its Price-To-Sales Ratio (1.1x) compared to the North American Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is MJRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MJRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MJRX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeuPath Health

CA$9.0m

Provides chronic pain management services in Canada.

NPTH

CA$0.15

-3.1%

-13.9%

Hamilton Thorne

CA$345.3m

Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.

HTL

CA$2.23

-0.9%

90.6%

Medical Facilities

CA$380.1m

Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.

CA$15.99

1.7%

79.8%